2024
A comparison of chemiluminescent immunoassay and enzyme-linked immunosorbent assay for detecting phospholipase A2 receptor antibody in primary membranous nephropathy
Ma X, Wang R, Wei L, Liu P, Jing L, Wang J, Dong W, Tian X, Fu R. A comparison of chemiluminescent immunoassay and enzyme-linked immunosorbent assay for detecting phospholipase A2 receptor antibody in primary membranous nephropathy. Practical Laboratory Medicine 2024, 39: e00385. PMID: 38495349, PMCID: PMC10940994, DOI: 10.1016/j.plabm.2024.e00385.Peer-Reviewed Original ResearchAnti-PLA2R antibodiesEnzyme-linked immunosorbent assayNegative predictive valuePositive predictive valueAnti-PLA2RMembranous nephropathyChemiluminescence immunoassayLevels of anti-PLA2R antibodiesPhospholipase A2 receptor antibodyPredictive valuePrimary membranous nephropathyPhospholipase A2 receptorImmunosorbent assayResults Serum levelsStatistical analysis of sensitivityROC curve analysisNon-membranous nephropathyStatistically significant differencePMN groupReceptor antibodiesSerum levelsA2 receptorsSpearman correlation analysisDiagnostic valueNephropathy
2023
IgG4-Related Disease with IgG1-Dominant Membranous Nephropathy: A Rare Case Report
Duan Y, Qu Y, Zhuang J, Abudula R, Zhang C, Tian X, Jiang H. IgG4-Related Disease with IgG1-Dominant Membranous Nephropathy: A Rare Case Report. Integrative Medicine In Nephrology And Andrology 2023, 10: e00007. DOI: 10.1097/imna-d-23-00007.Peer-Reviewed Case Reports and Technical NotesMembranous nephropathyClinical remissionIgG4-RDNephrotic syndromeIgG4-related tubulointerstitial nephritisRare pathological featureComplete clinical remissionPrimary membranous nephropathyRare case reportGlucocorticoid therapyPLA2R stainingKidney involvementMaintenance therapyRituximab treatmentRTX treatmentImmunoglobulin G4Tubulointerstitial nephritisKidney biopsySubepithelial depositionPathological featuresCase reportFibroinflammatory disorderAntigen stainingNephropathyReceptor antigen
2021
Effect of Mahuang Fuzi and Shenzhuo Decoction on Idiopathic Membranous Nephropathy: A Multicenter, Nonrandomized, Single-Arm Clinical Trial
Dong Z, Dai H, Gao Y, Jiang H, Liu M, Liu F, Liu W, Feng Z, Zhang X, Ren A, Li X, Rui H, Tian X, Li G, Liu B. Effect of Mahuang Fuzi and Shenzhuo Decoction on Idiopathic Membranous Nephropathy: A Multicenter, Nonrandomized, Single-Arm Clinical Trial. Frontiers In Pharmacology 2021, 12: 724744. PMID: 34733157, PMCID: PMC8558382, DOI: 10.3389/fphar.2021.724744.Peer-Reviewed Original ResearchIdiopathic membranous nephropathySingle-arm clinical trialMahuang-FuziMembranous nephropathyCourse of treatmentRemission rateImmunosuppressive therapyDisease remissionUrine proteinClinical trialsSevere adverse eventsCases of patientsMean followAdverse eventsRenal functionClinical effectsNephropathyPatientsBlood albuminRemissionTherapyDecoctionMulticenterObjective performance criteriaTreatment